Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 12:04PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.13 Insider Own15.86% Shs Outstand30.10M Perf Week-12.91%
Market Cap95.64M Forward P/E- EPS next Y-2.24 Insider Trans3.72% Shs Float25.39M Perf Month-18.09%
Income-94.30M PEG- EPS next Q-0.81 Inst Own47.73% Short Float6.45% Perf Quarter-44.29%
Sales0.00M P/S- EPS this Y10.06% Inst Trans4.25% Short Ratio10.95 Perf Half Y13.21%
Book/sh2.39 P/B1.33 EPS next Y24.14% ROA-85.74% Short Interest1.64M Perf Year-0.16%
Cash/sh2.77 P/C1.14 EPS next 5Y- ROE-95.48% 52W Range2.36 - 7.22 Perf YTD-23.43%
Dividend Est.- P/FCF- EPS past 5Y-2.94% ROI-130.89% 52W High-56.11% Beta0.40
Dividend TTM- Quick Ratio6.82 Sales past 5Y0.00% Gross Margin- 52W Low34.32% ATR (14)0.27
Dividend Ex-Date- Current Ratio6.82 EPS Y/Y TTM34.48% Oper. Margin0.00% RSI (14)28.89 Volatility5.96% 7.04%
Employees20 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom2.20 Target Price10.88
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q17.16% Payout- Rel Volume1.23 Prev Close3.24
Sales Surprise- EPS Surprise15.29% Sales Q/Q- EarningsMay 08 AMC Avg Volume149.59K Price3.17
SMA20-13.28% SMA50-27.07% SMA200-15.71% Trades Volume78,615 Change-2.16%
Date Action Analyst Rating Change Price Target Change
Oct-14-22Downgrade Truist Buy → Hold $90 → $10
Oct-14-22Downgrade Guggenheim Buy → Neutral
Oct-14-22Downgrade Goldman Buy → Neutral $81 → $8
Oct-13-22Downgrade Oppenheimer Outperform → Perform $64 → $7
Nov-18-21Initiated Mizuho Buy $50
May-20-21Resumed Goldman Buy $78
Oct-28-20Downgrade Goldman Buy → Neutral $69 → $40
Jul-14-20Initiated Oppenheimer Outperform $75
May-04-20Initiated SunTrust Buy $75
Apr-21-20Initiated Goldman Buy $63
May-11-24 08:41AM
May-09-24 06:20AM
May-08-24 09:55PM
07:30AM Loading…
May-06-24 07:30AM
Mar-20-24 10:27AM
Mar-19-24 08:52PM
Mar-12-24 07:30AM
Mar-05-24 07:30AM
Feb-01-24 03:02PM
Jan-05-24 05:12PM
07:30AM Loading…
Jan-04-24 07:30AM
Dec-29-23 08:47AM
Dec-20-23 02:39PM
Nov-10-23 01:57PM
Nov-08-23 06:47PM
Nov-03-23 07:30AM
Oct-11-23 08:31AM
Oct-09-23 07:30AM
Oct-06-23 07:30AM
Sep-20-23 08:30AM
Aug-23-23 07:30AM
Aug-08-23 04:01PM
Aug-01-23 07:30AM
06:10AM Loading…
Jul-31-23 06:10AM
Jun-08-23 07:30AM
Jun-02-23 07:30AM
May-24-23 07:42AM
May-11-23 04:01PM
May-08-23 07:30AM
Apr-12-23 12:59PM
Mar-27-23 07:12AM
Mar-24-23 09:08AM
Mar-23-23 04:01PM
Mar-17-23 08:30AM
Feb-27-23 09:13AM
Feb-17-23 06:35AM
Jan-12-23 08:00AM
Jan-09-23 08:00AM
Dec-29-22 09:11AM
Dec-15-22 06:08AM
Dec-08-22 08:39AM
Dec-07-22 04:05PM
Nov-10-22 04:05PM
Nov-08-22 04:15PM
Nov-03-22 12:24PM
Oct-20-22 11:28AM
Oct-14-22 12:55PM
Oct-13-22 04:04PM
Sep-20-22 08:30AM
Aug-14-22 10:14AM
Aug-11-22 04:15PM
Aug-09-22 08:30AM
Aug-05-22 08:30AM
Jul-21-22 08:30AM
Jul-04-22 06:51AM
Jun-07-22 08:30AM
Jun-02-22 08:30AM
May-25-22 08:30AM
May-10-22 12:25PM
May-05-22 04:01PM
Apr-29-22 08:30AM
Apr-28-22 09:00AM
Apr-04-22 09:00AM
Mar-23-22 04:05PM
Mar-16-22 08:30AM
Mar-10-22 08:30AM
Mar-09-22 01:24AM
Mar-08-22 04:00PM
Mar-07-22 05:32PM
Mar-05-22 05:30AM
Mar-03-22 02:04PM
Mar-02-22 01:28PM
Feb-27-22 06:24AM
Feb-23-22 11:42AM
Feb-10-22 08:30AM
Jan-12-22 10:00AM
Dec-22-21 09:02AM
Dec-15-21 09:20AM
Dec-14-21 08:30AM
Dec-09-21 07:23AM
Dec-08-21 11:21PM
Dec-01-21 08:30AM
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TRAVERSA SERGIOChief Executive OfficerJan 31 '24Buy4.0027,460109,752244,024Jan 31 06:29 PM
Ence ChuckCA and COJan 31 '24Buy4.0513,67055,42938,970Jan 31 06:28 PM
Shenouda MagedChief Financial OfficerJan 31 '24Buy4.066,87527,94334,903Jan 31 06:28 PM
TRAVERSA SERGIOChief Executive OfficerJan 30 '24Buy3.9040,999159,949216,564Jan 31 06:29 PM
Shenouda MagedChief Financial OfficerJan 30 '24Buy3.8915,00058,32328,028Jan 31 06:28 PM
Ence ChuckCA and COJan 30 '24Buy3.8714,50056,05325,300Jan 31 06:28 PM
TRAVERSA SERGIOChief Executive OfficerJan 29 '24Buy3.7131,541117,036175,565Jan 31 06:29 PM
Shenouda MagedChief Financial OfficerJan 29 '24Buy3.6510,80039,45013,028Jan 31 06:28 PM
Ence ChuckCA and COJan 29 '24Buy3.6510,80039,43810,800Jan 31 06:28 PM
O'Gorman CedricChief Medical OfficerMay 23 '23Buy3.1810,00031,80010,121May 24 09:00 AM